Domo signs strategic collaboration agreement with AWS for AI solutions
On Wednesday, Intensity Therapeutics , Inc. (NASDAQ:INTS), a $34.6 million market cap biotechnology company, maintained its Speculative Buy rating and $4.00 price target from Benchmark analysts. According to InvestingPro data, analyst price targets range from $4 to $16, suggesting significant upside potential. The company recently disclosed its financial outcomes for the fourth quarter of 2024 and provided an update on its corporate status at the year’s end. Intensity Therapeutics experienced a net loss of $16.3 million for the year, which translates to a loss of $1.17 per share. This is in contrast to the previous year’s net loss of $11.9 million, or $1.38 per share.
The fourth-quarter results revealed a net loss of $3.2 million, or $0.22 per share. This included research and development costs totaling $2.0 million and general and administrative expenses of $1.2 million. The company’s lead pipeline program, INT230-6, has been a focal point of recent achievements. This includes the screening of 25 patients for the INVINCIBLE-3 Phase 3 study, which evaluates INT230-6 as a standalone therapy in the second and third lines of treatment for certain soft tissue sarcoma subtypes.
Additionally, Intensity Therapeutics has expanded its clinical reach by activating eight sites in Europe for the INVINCIBLE-4 study. This Phase 2 trial involves the use of INT230-6 in the treatment of patients with early-stage, operable triple-negative breast cancer (TNBC). The company’s continued progress in these clinical trials has been a notable component of its latest corporate developments.
In other recent news, Intensity Therapeutics, Inc. announced that its Phase 3 sarcoma trial, INVINCIBLE-3, will continue as planned after a six-month review by the Data Monitoring Committee. This decision allows the ongoing testing of INT230-6, an intratumoral injection, against standard-of-care chemotherapy for patients with certain types of soft tissue sarcoma. The trial, which involves approximately 333 adult participants, aims to measure overall survival, safety, and quality of life. Participants in the study include those with leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The trial is currently recruiting in the U.S., Canada, and Europe with necessary authorizations from relevant health agencies. INT230-6 utilizes Intensity’s DfuseRx™ technology platform, combining cisplatin and vinblastine sulfate with a penetration enhancer for targeted tumor treatment. This approach seeks to kill tumors directly and stimulate an immune response without causing systemic immunosuppression. The company has previously conducted clinical studies with INT230-6 in metastatic and breast cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.